This study proved the benefit of the FGF2-targeting system, which has high transduction efficiency and enables a lower titre viral administration while still maintaining in vitro and in vivo tumour suppressive effect of cisplatin equivalent to a higher titre non-targeting transfer. This evidence concerns the gene FGF2 and neoplasm.